Even in models of relatively rare autoimmune diseases like primary sclerosing cholangitis, inhibition of the SASP of senescent cholangiocytes through Bcl-2 inhibition reduced tissue damage and subsequent fibrosis [128]. This evidence concerns the gene BCL2 and sclerosing cholangitis.